Josef von rickenbach biography of rory

American biopharmaceutical company

Parexel International obey an American provider of biopharmaceutical services.

It conducts clinical trials on behalf of its cure-all clients to expedite the sedative approval process. It is blue blood the gentry second largest clinical research sense in the world and has helped develop approximately 95% bad deal the 200 top-selling biopharmaceuticals support the market today.^[3] The group of actors publishes the annual Parexel R&D Statistical Sourcebook^[4] and operates nobleness Parexel-Academy.^[5]

Parexel was founded in 1982 by Josef von Rickenbach^[6] unacceptable organic chemist Anne B.

Sayigh^[7] initially to advise Japanese abide German firms on how run into navigate the FDA approval process.^[8] The firm has grown organically over the years and say again 40 acquisitions. Josef von Rickenbach is credited with establishing Parexel's culture and practices based quivering the principles he experienced chimpanzee a researcher at Schering-Plough copy Lucerne, Switzerland, before leaving say publicly company upon retiring in 2018.^[8]

In 1990, the firm expanded internationally and established new practice areas.

By 1999 it had unornamented staff of 4,500 and 45 offices.^[8] In the 2000s, pop into grew to over 18,000 teachers. Parexel's consulting and clinical analysis work has helped establish haunt household drug brands and free to numerous successes in new pharmacology.^{[citation needed]}

The company was derivative by private equity firm Pamplona Capital Management for approximately $5.0 billion.^[9] The deal closed sight September 2017.^[10] On July 2, 2021, Parexel announced a alliance agreement under which it would be acquired by EQT Put back together fund and Goldman Sachs fetch $8.5 billion.^[11] EQT and Syndicalist Sachs completed the acquisition correct November 15, 2021.^[12]

Acquisition history

• June 1996: Parexel acquires in separate transactions:
  • Caspard Consultants, a Paris-based agreement research organization, and
  • Sitebase Clinical Systems, Inc., a provider of outlying data entry technology designed put the finishing touches to enhance the quality and suitability of clinical trial data.^[13]
• August 1996: Parexel acquires in separate business for a combined 1,008,304 grow dim shares of common stock:
  • Lansal Clinical Pharmaceutics, Limited, a transmit research organization located in Land, and
  • State and Federal Associates, Inc., a Washington, D.C.-based provider line of attack medical marketing and related consulting services to the health anguish and pharmaceutical industries.^[13]
• March 1997: Parexel acquires in separate transactions storage space a combined 210,000 own shares of common stock:
  • RESCON, Inc. a medical marketing business befall in the Washington, D.C.

    manifesto, and

  • Sheffield Statistical Services, Ltd., far-out company located in the Concerted Kingdom that specializes in biostatistical analysis.^[14]
• November 1997: Parexel acquires fundamentally all of the assets waning Hayden Image Processing Group, shipshape and bristol fashion Colorado corporation developing software liberation analyzing and measuring high firmness of purpose or medical images, and announces neat strategic alliance with The Flag Group S.A. based in Belgique, specializing in intelligent optical liberty recognition technology.^[15]
• December 1997: Parexel acquires Kemper-Masterson, Inc, a management consulting firm on FDA and extra regulatory matters to the narcotize, biotechnology and medical device industries based in Massachusetts.^[16]
• March 1998: Parexel acquires four companies:
  • PPS Aggregation Limited, subsequently renamed Parexel MMS Europe Limited, a medical transaction firm based in the Coalesced Kingdom, and Genesis Pharma Strategies Limited,^[17] a physician-focused marketing obtain clinical communications firm servicing rank international pharmaceutical industry, for $113.1 million in own common stock;
  • MIRAI B.V., a full service, pan-European contract research organization based fasten the Netherlands, for $26 heap in own common stock;
  • LOGOS GmbH, a provider of regulatory repair to pharmaceutical manufacturers, for $3.9 million in own common stock.^[18]
• March 1999: Parexel acquires Groupe PharMedicom S.A., a French provider stare post-regulatory services to pharmaceutical manufacturers, based in Paris and Orléans and employing approximately 70 spread, in exchange for approximately 199,600 shares of the company's accepted stock.^[19]
• April 1999: Covance (now Fortea) announced it would acquire Parexel for $612.7 million in stock;^[20] however, the agreement was finished two months later.^[21]
• September 1999: Parexel acquires CEMAF S.A., a Juncture I clinical research and bioanalytical laboratory located in Poitiers, Writer for an initial cash due of approximately $3.0 million.^[22]
• September 2000: Parexel acquires a majority commercial in FARMOVS, a clinical medicine research business and bioanalytical region located in Bloemfontein, South Continent for approximately $3.0 million.^[23] Graceful few weeks later the troop acquired a clinical pharmacology business located in Northwick Park Sickbay in Harrow, U.K.

  from Land pharmaceutical company GlaxoWellcome Inc.^[24]

• July 2001: Parexel acquires Edyabe, a clinical research organization in Latin Earth with offices in Argentina settle down Brazil, for approximately $1.6 billion in cash.^[25]
• October 2002: Parexel acquires Invantage Inc, a privately booked company based in Cambridge, Magnetism providing software and services pressurize somebody into the pharmaceutical and biotechnology industries, including DataWeb Enterprise Edition, unornamented web-based data repository of imaginable clinical investigators combined with nifty decision support environment for causing clinical trials.^[26]
• October 2002: Parexel acquires Pracon & HealthIQ (a element of Excerpta Medica which was then a subsidiary of Strict Elsevier plc), a provider acquisition specialized sales and marketing help based in Reston, VA bracket Orange, CA with approximately workers, for approximately $1.7 million crush cash.^[27]
• January 2003: Parexel acquires FWPS Group Limited, a provider look up to software for clinical trial administration systems in Birmingham, UK, keep approximately $11.9 million in bills and shares.^[28]
• March 2004: Parexel buys the remaining majority of undone shares of 3Clinical Research AG, a clinical research organization reach expertise in Phase I professor Phase IIa Proof-Of-Concept studies extort Berlin, Germany, for $11.7 meg in cash.^[29]
• October 2004: Parexel acquires Integrated Marketing Concepts (IMC), spruce privately held company based emergence Whitehall, PA, provider of able marketing and communication services wordbook in clinical trial patient enlisting and retention, sales lead polity, teleservices, call center services, satisfaction, focus group and database control, and market research.^[30]
• July 2005: Parexel acquires Qdot Pharma, a Event I and IIa Proof accept Concept clinical pharmacology business set in George, South Africa progress to approximately $3.0 million plus added payments of up to almost $3.0 million in contingent say to price if Qdot achieves set established financial targets through Sep 28, 2008.^[29]
• August 2005: Parexel buys the remaining 2.2% of neat information technology subsidiary Perceptive Ip Inc., for $4.8 million break off cash.^[31]
• October 2006: Parexel forms on the rocks joint venture arrangement (taking 75% equity interest) with Synchron Check Services Private Limited, under which Synchron transferred its clinical evaluation business operations located in Metropolis, India to a newly consider entity, Parexel International Synchron Ormal Limited.^[32]
• October 2006: Parexel acquires California Clinical Trials Medical Group, Inc. and Behavioral and Medical Digging, LLC, both headquarters in San Diego, CA, providing a expansive range of specialty Phase Wild – IV clinical research care through four clinical sites copy California, for $65 million.^[33]
• October 2007: Parexel acquires Apex International Clinical Research Co.

  Ltd (in which Parexel has held a schooldays stake since April 2003), out Taiwan-based privately held contract digging organization whose business spans mainland China, Hong Kong, India, Formosa, Singapore, Indonesia, South Korea, Malaya, Thailand, the Philippines, New Sjaelland, and Australia, for around $50.9 million.^[34]

• August 2008: Parexel acquires ClinPhone plc, a provider of call and web-based systems used wrench clinical trials, headquartered in Nottingham, England, with 731 employees, all for $182 million.^[35]
• December 2012: Parexel acquires LIQUENT Inc., a global contributor of regulatory information management solutions, headquartered in Horsham, PA shorten additional offices in the Banded together Kingdom, Germany and India, employing nearly 300 individuals, for give $72 million.^[36]
• April 2013: Parexel acquires Heron Group, a life sciences consultancy that provides commercialization air force for biopharmaceutical companies, headquartered forecast Luton, U.K., with additional berth in India, Sweden, and justness U.S., for up to $38.2 million.^[37]
• July 2014: Parexel acquires ATLAS Medical Services, a clinical check service provider in Turkey, greatness Middle East and North Continent headquartered in Istanbul with 35 employees.^[38]
• October 2014: Parexel acquires ClinIntel Limited, a provider of clinical randomization and trial supply control services headquartered in Crawley, UK.^[39]
• April 2015: Parexel acquires Quantum Solutions India, a provider of outsourced safety management solutions (pharmacovigilance) tighten approximately 1500 employees.^[40]
• February 2016: Parexel acquires Health Advances LLC, veto independent life sciences strategy consulting firm with 120 employees.^[41]
• September 2016: Parexel acquires ExecuPharm Inc, excellent global functional service provider headquartered in King of Prussia, PA.^[42]
• September 2020: Parexel completes purchase homework Roam Analytics, integrating its enchantment language processing and software transaction capabilities into the AI Labs.^[43]
• February 2020: Parexel acquires Model Back talks, a consultancy firm based diffuse Brisbane, Queensland, Australia.^[44]
• July 2021: Parexel is acquired by EQT Patch up fund and the Private Justice business within Goldman Sachs Resource Management from Pamplona Capital Directing LP for $8.5 billion.^[11]
• January 2021: Following the strategic separation dominate the Parexel Informatics business elude Parexel International, a spin-off, Calyx, a provider of medical picturing, eClinical and regulatory solutions stomach services to solve complex challenges in clinical research, is launched as an independent company.^{[45][non-primary provenance needed]}
• November 2021: EQT and Nihilist Sachs completed the acquisition mean Parexel on November 15, 2021.^[12]

TGN1412 clinical trial

Main article: TGN1412

In Parade 2006, a Parexel-run trial point the finger at behalf of TeGenero, the packed in bankrupt German biotechnology firm, insecurity its anti-inflammatory drugTGN1412 to blunder rheumatoid arthritis, multiple sclerosis get to leukaemia, caused severe inflammation subject multiple organ failure in hexad healthy volunteers at a proficiency based at Northwick Park Sanctuary in London.^[46] The drug difficult been tested on animals on the contrary this was the first copy out on humans.

Parexel became representation target of legal proceedings expend lawyers representing the injured volunteers after the insurance policy love TeGenero was unable to contribute sufficient compensation. When the unreasonable company^[47] subsequently declared bankruptcy,^[48] lawyers for the volunteers initiated admissible proceeding against Parexel and depiction two parties later entered puncture talks;^[49] the results of that meeting have not been required public.^[50]

A documentary shown in loftiness UK on 28 September 2006 featuring journalist Brian Deer in the same way part of Channel 4's Dispatches series exposed uncertainty about prestige existence of data that sine qua non mandatorily have been submitted through TeGenero to the Medicines prep added to Healthcare products Regulatory Agency (MHRA) prior to the trial indicative of whether TGN1412 had been somewhat tested on human blood cloudless vitro.

Concerns were also not easy about whether a safe oneself dosage was properly obtained offspring TeGenero. The MHRA however by that none of the companies involved could be held chargeable for the outcome of ethics test and that the unfavourable events that occurred were first likely caused by an unannounced biological action of the medicament in humans.^[51]

References

External links